Fundraising Fox
RheumaGen
Denver, US · Founded 2022 · Delaware corporation · 1 known investors
Find your way into RheumaGen
371 people in our graph can introduce you to the RheumaGen team.
Sign up to see every warm intro you have to RheumaGen
- Paths you didn't know you had: your email and LinkedIn already hold routes to the RheumaGen team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
RheumaGen is a private biotechnology company developing one-time cell and gene therapies that edit the human leukocyte antigen (HLA) to treat autoimmune diseases at their source. It works with the University of Colorado Anschutz Medical Campus and its ClinImmune laboratory to advance clinical programs.
Founders & leadership
RheumaGen was founded in 2022 by Richard Freed, Brian Hart, and Brian Freed.
BH
Brian HartCOO & Co-FounderCOO and co-founder of RheumaGen, a biotechnology company developing cell and gene therapies for autoimmune diseases. Brian Hart previously worked as a business and nonprofit leader and attorney, and co-founded the organization in 2018.
BF
Brian FreedChief Science Officer & Co-Founder
RH
Ryan HartChief Business and Legal Officer
JB
James Brian Hart, Jr.Named on SEC filing
GL
Gregory L. AndrewsNamed on SEC filing
RA
Richard Anthony Freed, IIINamed on SEC filing
Investors · 1
Also in the syndicate · 1
Beyond Celiac Investments
Funding
SEC filings, press & company announcements$22.9M disclosed across 5 of 6 rounds · 2022–2025
- Undisclosed amountSeries A-1Dec 2025
Beyond Celiac Investments
Source ↗ - $15MSeries AJan 2025 · 3 sourcesSource ↗
▶$4.9MraisedApr 2024 · 3 investors · BiotechnologyRule 506(b)
▶$4.9MraisedApr 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ryan Kane HartExecutive Officer
- Bobak Robert MozayeniExecutive Officer
- Bruce Michael GoodwinDirector
- Thomas FratacciDirector
- Brian Matthew FreedExecutive Officer
- Richard Anthony Freed, IIIExecutive Officer, Director
- James Brian Hart, Jr.Executive Officer
- Offering amount
- $15M
- Amount sold
- $4.9M
- Proceeds to insiders
- $3M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$700KraisedApr 2024 · 1 investors · BiotechnologyRule 506(b)
▶$700KraisedApr 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bruce Michael GoodwinDirector
- James Brian Hart, Jr.Executive Officer
- Bobak Robert MozayeniExecutive Officer
- Ryan Kane HartExecutive Officer
- Thomas FratacciDirector
- Brian Matthew FreedExecutive Officer
- Richard Anthony Freed, IIIExecutive Officer, Director
- Offering amount
- $700K
- Amount sold
- $700K
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$300KraisedMay 2023 · 1 investors · BiotechnologyRule 506(b)
▶$300KraisedMay 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James Brian Hart, Jr.Executive Officer
- Brian M. FreedExecutive Officer, Director
- Gregory L. AndrewsDirector
- Richard Anthony Freed, IIIExecutive Officer, Director
- Ryan Kane HartExecutive Officer
- Offering amount
- $300K
- Amount sold
- $300K
- Minimum investment
- $300K
- Proceeds to insiders
- $243.7K
- First sale
- May 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$2MraisedOct 2022 · 1 investors · BiotechnologyRule 506(b)
▶$2MraisedOct 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James Brian Hart, Jr.Executive Officer
- Ryan Kane HartExecutive Officer
- Gregory L. AndrewsDirector
- Richard Anthony Freed, IIIExecutive Officer, Director
- Brian M. FreedExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- Minimum investment
- $2M
- Proceeds to insiders
- $970.2K
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
Biogen IdecBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
AmgenAmgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis. Its Danish operation, Amgen Danmark, focuses on improving health outcomes for patients and their families in Denmark.
NervGen PharmaNervGen is a clinical-stage biotech company developing therapies for neurological conditions, with a focus on spinal cord injury and neurorepair. It maintains a drug pipeline and operates as a publicly traded company.
UrogenUroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology. The company commercializes approved therapies for bladder and upper tract cancers, with additional candidates in development.
PepGenPepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.
Regeneron NASDAQ: REGN www.regeneron.comRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Companies working in the same space as RheumaGen.
In the news
Frequently asked questions
- What does RheumaGen do?
- RheumaGen is a private biotechnology company developing one-time cell and gene therapies that edit the human leukocyte antigen (HLA) to treat autoimmune diseases at their source. It works with the University of Colorado Anschutz Medical Campus and its ClinImmune laboratory to advance clinical programs.
- Who founded RheumaGen?
- RheumaGen was founded by Richard Freed, Brian Hart, Brian Freed in 2022.
- How much funding has RheumaGen raised?
- RheumaGen has disclosed $22.9M raised across 5 of its 6 known rounds.
- Where is RheumaGen headquartered?
- RheumaGen is headquartered in Denver, US.